Aoupuma: Intends to purchase 100% equity of Pengli Biology, with uncertainties.

Aopumai announcement, Shanghai Aopumai Biotechnology Co., Ltd. plans to purchase 100.00% equity of Pengli Biopharmaceutical Technology Co., Ltd. through the issuance of shares and payment of cash, and to issue shares to no more than 35 specific investors to raise supporting funds. This transaction is subject to the satisfaction of several conditions before it can be implemented, including but not limited to approval by the Shanghai Stock Exchange, approval by the China Securities Regulatory Commission for registration, etc. There is uncertainty regarding whether this transaction will ultimately obtain the above-mentioned approvals and registrations, as well as the time for obtaining approval and registration.